FTRE trades 2.5% below Wall Street's consensus target of $20.00.
Last 12 months price action with 12-month analyst target path
The base valuation assumes FTRE achieves its forward estimates and maintains a stable P/E multiple of 23.2x. This scenario reflects the blended consensus of 12 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of September 24, 2026, Fortrea Holdings Inc. (FTRE) has a Wall Street consensus price target of $20.00, based on estimates from 12 covering analysts. With the stock currently trading at $19.52, this represents a potential upside of +2.5%. The company has a market capitalization of $1.86B.
Analyst price targets range from a low of $16.00 to a high of $23.00, representing a 35% spread in expectations. The median target of $20.00 aligns closely with the consensus average.
The current analyst consensus rating is Hold, with 5 analysts rating the stock as a Buy or Strong Buy,6 rating it Hold, and 1 rating it Sell or Strong Sell. The mixed ratings reflect uncertainty about near-term direction.
From a valuation perspective, FTRE trades at a trailing P/E of -1.8x and forward P/E of 23.2x. Analysts expect EPS to grow +193.0% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 IQVIQVIA Holdings Inc. | $44.1B | $267.86 | $246.13 | -8.1% | Buy | 20.7x | 45 |
 CRLCharles River Laboratories International, Inc. | $13.4B | $277.33 | $282.36 | +1.8% | Buy | 24.5x | 37 |
 MEDPMedpace Holdings, Inc. | $17.2B | $617.15 | $606.38 | -1.7% | Hold | 35.1x | 19 |
 PRAProAssurance Corporation | $1.3B | $25.00 | $18.33 | -26.7% | Hold | 20.4x | 11 |
 ICLRICON Public Limited Company | $12.5B | $163.90 | $170.64 | +4.1% | Buy | 15.5x | 30 |
 LHLabcorp Holdings Inc. | $24.9B | $303.98 | $337.29 | +11.0% | Buy | 16.6x | 35 |
 DGXQuest Diagnostics Incorporated | $25.7B | $233.00 | $246.67 | +5.9% | Hold | 20.8x | 34 |
 NVCRNovocure Ltd | $1.9B | $16.25 | $26.00 | +60.0% | Buy | — | 15 |
 HIMSHims & Hers Health, Inc. | $6.3B | $28.39 | $32.17 | +13.3% | Hold | — | 20 |
 TMOThermo Fisher Scientific Inc. | $247.2B | $665.30 | $623.36 | -6.3% | Buy | 26.5x | 43 |
Quick answers to the most common questions about buying FTRE stock.
The consensus price target for FTRE is $20, close to the current price of $19.52 (2.5% implied move). Based on 12 analyst estimates, the stock appears fairly valued near current levels.
FTRE has a consensus rating of "Hold" based on 12 Wall Street analysts. The rating breakdown is mixed, with 6 Hold ratings making up the largest segment. The consensus 12-month price target of $20 implies 2.5% upside from current levels.
FTRE trades at a forward P/E of 23.2326x, representing a moderate valuation. With analysts targeting $20 (2.5% implied move), the stock appears close to fair value.
The most bullish Wall Street analyst has a price target of $23 for FTRE, while the most conservative target is $16. The consensus of $20 represents the median expectation. These targets typically reflect 12-month expectations.
FTRE is moderately covered, with 12 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 5 have Buy ratings, 6 recommend Hold, and 1 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month FTRE stock forecast based on 12 Wall Street analysts shows a consensus price target of $20, with estimates ranging from $16 (bear case) to $23 (bull case). The median consensus rating is "Hold".
FTRE trades at a forward P/E ratio of 23.2x based on next-twelve-months earnings estimates. The higher forward P/E suggests near-term earnings pressure. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
FTRE appears fairly valued according to analysts, with a "Hold" rating and minimal upside to the $20 target. Consider your investment thesis and risk tolerance. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
FTRE analyst price targets range from $16 to $23, a 35% moderate spread showing some variance in outlooks. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $20 consensus represents the middle ground.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.